A Study to Validate 5-hydroxyindoleacetic Acid in Plasma and Urine

Overview

About this study

This study aims to clinically validate two new liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays for 5-hydroxyindole-3-acetic acid (5-HIAA) in (1) human plasma, and (2) randomly collected urine specimens, and to determine true plasma and random urine 5HIAA levels in those confirmed in or suspected of having carcinoid syndrome (CS); thus establishing a disease range to compare to previously-established normal ranges.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Competent patients over 18 years of age.
Have or are suspected of having carcinoid syndrome (CS).

Exclusion Criteria:

All others.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Silvia Tortorelli, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Silvia Tortorelli, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials